BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (PRNewswire) - May 14, 2024 - "BrainStorm will participate in the forthcoming 3rd Annual ALS Drug Development Summit, to take place May 21 to 23, 2024 in Boston MA. Dr. Stacy Lindborg will deliver a presentation Promising Longer-Term Biomarker Data from NurOwn Program in ALS: Spotlight on NfL in EAP Extension Cohort. The new data to be presented suggest that patients may benefit from longer term treatment with NurOwn, as evidenced by changes in neurofilament light (NfL), an important biomarker associated with clinical outcomes in ALS."
Biomarker • P3 data • Amyotrophic Lateral Sclerosis • CNS Disorders
|